Efficacy of epinastine hydrochloride ophthalmic solution after switched from olopatadine hydrochloride ophthalmic solution in elderly patients with perennial allergic conjunctivitis.

Trial Profile

Efficacy of epinastine hydrochloride ophthalmic solution after switched from olopatadine hydrochloride ophthalmic solution in elderly patients with perennial allergic conjunctivitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Epinastine (Primary)
  • Indications Allergic conjunctivitis
  • Focus Therapeutic Use
  • Sponsors Santen Pharmaceutical
  • Most Recent Events

    • 03 Jun 2016 Status changed from recruiting to completed.
    • 09 Dec 2015 Planned End Date changed from 31 Mar 2015 to 31 Dec 2015 as reported by University hospital Medical Information Network-Japan record.
    • 04 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top